Related Experiment Video
Updated: Aug 11, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review
Yuki Yoshimatsu1,2, Noriyuki Ebi1, Ryunosuke Ooi1
1Department of Respiratory Medicine, Iizuka Hospital, Japan.
Abstract:
The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung squamous cell carcinoma is said to be low. Thus far, only four cases of osimertinib in lung squamous cell carcinoma have been published. We experienced a case of EGFR mutant lung squamous cell carcinoma in which fifth-line treatment with osimertinib was effective after T790M EGFR mutation turned positive. Osimertinib was resumed after sixth-line chemotherapy was ineffective, showing efficacy again. Osimertinib may be a promising treatment option for EGFR mutant lung squamous cell carcinoma. This is the first report to show its effect in a case of rechallenge after intervening chemotherapy. It may therefore be important to evaluate EGFR in never-smoker lung squamous cell carcinoma patients.
Insights
Osimertinib shows efficacy in EGFR-mutated lung squamous cell carcinoma, even after other treatments. This study highlights its potential for rechallenge therapy in advanced cases.
Area of Science:
- Oncology
- Medical Genetics
- Pharmacology
Background:
- Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have limited efficacy in lung squamous cell carcinoma.
- Published cases of osimertinib use in this subtype are scarce.
Observation:
- A patient with EGFR-mutated LSCC experienced positive response to fifth-line osimertinib treatment following the emergence of a T790M EGFR mutation.
- Following ineffective sixth-line chemotherapy, osimertinib was reintroduced and demonstrated renewed efficacy.
Findings:
- This case demonstrates the effectiveness of osimertinib in LSCC with EGFR mutations, including T790M.
- The study reports the first instance of successful osimertinib rechallenge after intervening chemotherapy in LSCC.
Implications:
- Osimertinib may represent a viable treatment option for patients with EGFR-mutated LSCC.
- Evaluating EGFR status, particularly in never-smoker LSCC patients, is crucial for treatment selection.
- Rechallenging with osimertinib warrants consideration in advanced LSCC after progression on other therapies.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
